Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS
NCT07923552, Not applicable, Recruiting, University Hospital, Clermont-Ferrand
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS | ClinicalTrials.gov |
| NCT number | NCT07923552 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 48 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Clermont-Ferrand | ClinicalTrials.gov |
| Conditions | PCOS (Polycystic Ovary Syndrome) | ClinicalTrials.gov |
| Interventions | ovarian drilling by abdominal Laparoscopy, Ovarian drilling by vaginal laparoscopy VNotes | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | The resumption (or not) of an ovulatory cycle | at the 6 months follow-up visit | The resumption (or not) of an ovulatory cycle will be evaluated during the 6 months follow-up visit after the intervention. The resumption of cycles is defined by cycles lasting more than 3 months, an elevated progesterone level, or the presence of a corpus luteum on ultrasound." | ClinicalTrials.gov |
| Secondary | Pain assessment | 1 hour during ambulatory care | For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 1 hour during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable | ClinicalTrials.gov |
| Secondary | pain assessment | 6 hours during ambulatory care | For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 6 hours during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable | ClinicalTrials.gov |
| Secondary | pain assessment | on day 1 after the intervention | For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient through a questionnaire sent to the patients on Day 1 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable | ClinicalTrials.gov |
| Secondary | pain assessment | on day 7 after the intervention | For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient on Day 7 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable | ClinicalTrials.gov |
| Secondary | pain assessment | at the postoperative follow-up visit (1 month) | For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient during the postoperative follow-up visit. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable | ClinicalTrials.gov |
| Secondary | The use of analgesics | up to 2 hours postoperatively | For each arm: The use of analgesics (yes/no) recorded up to 2 hours postoperatively | ClinicalTrials.gov |
| Secondary | The use of analgesics | up to 24 hours postoperatively | For each arm: The use of analgesics (yes/no) recorded up to 24 hours postoperatively | ClinicalTrials.gov |
| Secondary | The use of analgesics | postoperatively on Day 1 | For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on Day 1. | ClinicalTrials.gov |
| Secondary | The use of analgesics | postoperatively on Day 7 | For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on day 7 | ClinicalTrials.gov |
| Secondary | The use of analgesics | at the postoperative follow-up visit (1 month) | For each arm: The use of analgesics (yes/no) recorded at the postoperative follow-up visit (1 month) | ClinicalTrials.gov |
| Secondary | The operative duration | peroperatively | For each arm: The operative duration from incision to closure recorded in the operating room, as well as the operative duration from the introduction of the Palmer needle in laparoscopy and the vaginal incision in VNotes until closure | ClinicalTrials.gov |
| Secondary | Rehospitalization due to complications | at the postoperative follow-up visit (1 month) | for each arm: Rehospitalization due to complications from the operation within the month following the procedure (yes/no), at the postoperative follow-up visit (1 month) | ClinicalTrials.gov |
| Secondary | Extension of the initial sick leave (yes/no) | at the postoperative follow-up visit (1 month) | For each arm: Extension of the initial sick leave (yes/no), assessed at the postoperative follow-up visit (1 month) | ClinicalTrials.gov |
| Secondary | The presence of intraoperative complications | during the intervention | for each arm: The presence of intraoperative complications recorded during the intervention according to the Clavien-Dindo classification, including whether a conversion occurred, and the number of such complications | ClinicalTrials.gov |
| Secondary | extension of the ambulatory stay (yes/no) | Upon discharge from hospitalization (assessed up to 5 days) | For each arm: The use of an extension of the ambulatory stay (yes/no) and the total duration of hospitalization in days and hours | ClinicalTrials.gov |
| Secondary | The occurrence of a pregnancy | one year after the 6 months follow-up visit | The occurrence of a spontaneous pregnancy, IVF, twin pregnancy, or OHSS if IVF, assessed one year after the 6 months follow-up visit | ClinicalTrials.gov |
| Secondary | The measurement of AMH | at the preoperative visit (1 month before the intervention) | The measurement of AMH in nanograms/mL at the preoperative visit (1 month before the intervention) | ClinicalTrials.gov |
| Secondary | The measurement of AMH | at the postoperative follow-up visit (1 month) | The measurement of AMH in nanograms/mL at the postoperative follow-up visit (1month). | ClinicalTrials.gov |
| Secondary | The measurement of AMH | at the 6 Months follow-up visit | The measurement of AMH in nanograms/mL at the Month 6 follow-up visit | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)